What Happened?
Burlington, MA-based Aldeyra-Therapeutics,-Inc Appointed Todd Brady as Chief Executive Officer
About the Company
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.
About the Person
Todd Brady is Chief Executive Officer at Aldeyra Therapeutics, Inc. Previously, Todd held various senior HR leadership roles in the industry.
Info Source
News
Short Profile